SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma
Copyright © 2020 Elsevier Ltd. All rights reserved..
SARS-CoV-2 has infected millions worldwide. The virus is novel, and currently there is no approved treatment. Convalescent plasma may offer a treatment option. We evaluated trends of IgM/IgG antibodies/plasma viral load in donors and recipients of convalescent plasma. 114/139 (82 %) donors had positive IgG antibodies. 46/114 donors tested positive a second time by NP swab. Among those retested, the median IgG declined (p < 0.01) between tests. 25/139 donors with confirmed SARS-CoV-2 were negative for IgG antibodies. This suggests that having had the infection does not necessarily convey immunity, or there is a short duration of immunity associated with a decline in antibodies. Plasma viral load obtained on 35/39 plasma recipients showed 22 (62.9 %) had non-detectable levels on average 14.5 days from positive test versus 6.2 days in those with detectable levels (p < 0.01). There was a relationship between IgG and viral load. IgG was higher in those with non-detectable viral loads. There was no relationship between viral load and blood type (p = 0.87) or death (0.80). Recipients with detectable viral load had lower IgG levels; there was no relationship between viral load, blood type or death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis - 59(2020), 6 vom: 07. Dez., Seite 102922 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dulipsingh, Latha [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.12.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.transci.2020.102922 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31456439X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31456439X | ||
| 003 | DE-627 | ||
| 005 | 20231225153012.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transci.2020.102922 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM31456439X | ||
| 035 | |a (NLM)32883593 | ||
| 035 | |a (PII)S1473-0502(20)30236-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dulipsingh, Latha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a SARS-CoV-2 has infected millions worldwide. The virus is novel, and currently there is no approved treatment. Convalescent plasma may offer a treatment option. We evaluated trends of IgM/IgG antibodies/plasma viral load in donors and recipients of convalescent plasma. 114/139 (82 %) donors had positive IgG antibodies. 46/114 donors tested positive a second time by NP swab. Among those retested, the median IgG declined (p < 0.01) between tests. 25/139 donors with confirmed SARS-CoV-2 were negative for IgG antibodies. This suggests that having had the infection does not necessarily convey immunity, or there is a short duration of immunity associated with a decline in antibodies. Plasma viral load obtained on 35/39 plasma recipients showed 22 (62.9 %) had non-detectable levels on average 14.5 days from positive test versus 6.2 days in those with detectable levels (p < 0.01). There was a relationship between IgG and viral load. IgG was higher in those with non-detectable viral loads. There was no relationship between viral load and blood type (p = 0.87) or death (0.80). Recipients with detectable viral load had lower IgG levels; there was no relationship between viral load, blood type or death | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adults | |
| 650 | 4 | |a Antigens | |
| 650 | 4 | |a Blood transfusion | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 serotherapy | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Coronavirus infections | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Immunoglobulin G | |
| 650 | 4 | |a Immunoglobulin M | |
| 650 | 4 | |a Plasma | |
| 650 | 4 | |a SARS virus | |
| 650 | 4 | |a Severe acute respiratory syndrome | |
| 650 | 4 | |a Severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a Viral | |
| 650 | 4 | |a Viral load | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Ibrahim, Danyal |e verfasserin |4 aut | |
| 700 | 1 | |a Schaefer, Ernst J |e verfasserin |4 aut | |
| 700 | 1 | |a Crowell, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Diffenderfer, Margaret R |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Kendra |e verfasserin |4 aut | |
| 700 | 1 | |a Lima, Colleen |e verfasserin |4 aut | |
| 700 | 1 | |a McKenzie, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Puff, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Onoroski, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Wakefield, Dorothy B |e verfasserin |4 aut | |
| 700 | 1 | |a Eadie, Reginald J |e verfasserin |4 aut | |
| 700 | 1 | |a Kleiboeker, Steven B |e verfasserin |4 aut | |
| 700 | 1 | |a Nabors, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Syed A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis |d 2001 |g 59(2020), 6 vom: 07. Dez., Seite 102922 |w (DE-627)NLM114008043 |x 1473-0502 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2020 |g number:6 |g day:07 |g month:12 |g pages:102922 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.transci.2020.102922 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2020 |e 6 |b 07 |c 12 |h 102922 | ||